Detection of Early-Stage Pancreatic Adenocarcinoma

摘要

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

主权项

1. A method of delivering a diagnostic or therapeutic agent to a pancreatic cancer cell comprising:
a) obtaining an anti-MUC-5ac antibody or antigen-binding fragment thereof that binds to the same epitope as or competes for binding to pancreatic cancer mucin with a chimeric PAM4 (cPAM4) antibody that comprises the light chain variable region CDR sequences CDR1 (SASSSVSSSYLY, (SEQ ID NO:1), CDR2 (STSNLAS, SEQ ID NO:2), and CDR3 (HQWNRYPYT, SEQ ID NO:3) and the heavy chain variable region CDR sequences CDR1 (SYVLH, SEQ ID NO:4), CDR2 (YINPYNDGTQYNEKFKG, SEQ ID NO:5) and CDR3 (GFGGSYGFAY, SEQ ID NO:6), wherein the anti-MUC-5ac antibody or antigen-binding fragment thereof is conjugated to a diagnostic or therapeutic agent; and b) exposing the pancreatic cancer cell to the conjugated anti-MUC-5ac antibody or antigen-binding fragment thereof.